Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

Adenosine A2A receptor (A2AR) antagonists are being investigated as promising treatment strategy for Parkinson's disease (PD). To test whether A2AR antagonists are beneficial in early PD stages we used MitoPark mice, a genetic model with gradual degeneration of DA cells. Daily treatment of youn...

Full description

Bibliographic Details
Main Authors: Daniel Marcellino, Eva Lindqvist, Marion Schneider, Christa E. Müller, Kjell Fuxe, Lars Olson, Dagmar Galter
Format: Article
Language:English
Published: Elsevier 2010-11-01
Series:Neurobiology of Disease
Subjects:
Striatum
Parkinson's disease
L-DOPA
Dopamine
Spontaneous locomotion
Drug-induced locomotor activity
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996110002329

Internet

http://www.sciencedirect.com/science/article/pii/S0969996110002329

Similar Items